Irvine, United States
ISTA Pharmaceuticals, founded in 2000, emerged as a dynamic specialty pharmaceutical enterprise in the United States, with a focus on eye care and allergy treatments. It gained recognition as the fourth largest branded prescription eye care business in its market, substantiated by a robust U.S. sales force of over 165 representatives.
With a diversified product portfolio, ISTA Pharmaceuticals brought forth significant treatments such as BROMDAY™ for ocular inflammation, BEPREVE® for allergy-induced ocular itching, ISTALOL® for managing glaucoma, and VITRASE® as a pharmaceutical spreading agent. This portfolio underscored its innovation and client-focused strategies in the ophthalmic and allergy drug sectors.
In June 2012, ISTA was acquired by Bausch + Lomb, which was subsequently integrated into Valeant in July 2013. This acquisition positioned the company within larger pharmaceutical ecosystems, potentially enhancing its market reach and product development capabilities.
Novaliq GmbH
Optinose